Thomas E. Rawson
Genentech
34 Papers
632 Citations
Thomas E. Rawson is an academic researcher from Genentech. The author has contributed to research in topics: Peptidomimetic & Transferase. The author has an hindex of 14, co-authored 34 publications. Previous affiliations of Thomas E. Rawson include University of Texas System.
Chat about Author
Papers
Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells
Guy L. James,Joseph L. Goldstein,Michael S. Brown,Thomas E. Rawson,Todd C. Somers,Robert S. McDowell,Craig W. Crowley,Brian K. Lucas,Arthur D. Levinson,James C. Marsters +9 more
TL;DR: The benzodiazepine peptidomimetics may be useful in the design of treatments for tumors in which oncogenic Ras proteins contribute to abnormal growth, such as that of the colon, lung, and pancreas.
689
From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold
Mcdowell Robert S,Brent Blackburn,Thomas R. Gadek,Lawrence R. McGee,Thomas E. Rawson,Mark Reynolds,Kirk Robarge,Todd C. Somers,Eugene D. Thorsett +8 more
118
Potent α4β1 Peptide Antagonists as Potential Anti-Inflammatory Agents
David Y. Jackson,Clifford Quan,Dean R. Artis,Thomas E. Rawson,Brent Blackburn,Martin E. Struble,Geraldine Fitzgerald,Kathryn S. Chan,Sheldon Mullins,John Burnier,Wayne J. Fairbrother,Kevin R Clark,Maureen Berisini,Henry Chui,Mark Renz,S Jones,Sherman Fong +16 more
TL;DR: Novel, highly potent, cyclic peptides are described that competitively inhibit alpha 4 beta 1 binding to VCAM-1 and fibronectin at sub nanomolar concentrations and provide a template for the structure-based design of small molecule antagonists of alpha 4 Beta 1-mediated cell adhesion processes.
106
Patent
ras FARNESYL TRANSFERASE INHIBITORS
James C. Marsters,Michael S. Brown,Craig W. Crowley,Goldstein Joseph L,Guy L. James,Robert S. McDowell,David Oare,Thomas E. Rawson,Mark Reynolds,Todd C. Somers +9 more
- 10 May 1994
TL;DR: In this paper, benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase (RFTS) for the treatment of diseases for which inhibition of the RFTS is indicated.
90
A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.
Thomas E. Rawson,Matthias Rüth,Elizabeth Blackwood,Dan Burdick,Laura Corson,Jenna Dotson,Jason Drummond,Carter Fields,Guy Georges,Bernhard Goller,Jason Halladay,Thomas Hunsaker,Tracy Kleinheinz,Hans-Willi Krell,Jun Li,Jun Liang,Anja Limberg,Angela McNutt,John Moffat,Gail Lewis Phillips,Yingqing Ran,Brian Safina,Mark Ultsch,Leslie Walker,Christian Wiesmann,Birong Zhang,Aihe Zhou,Bing-Yan Zhu,Petra Rüger,Andrea G. Cochran +29 more
TL;DR: A novel class of Aurora inhibitors based on a pentacyclic scaffold derived from two early lead structures improves upon the best properties of each parent and compares favorably to a previously reported Aurora inhibitor, 39 (VX-680).
60